← Back to front page
United States · Platforms & data · Yahoo Finance

SCIENTURE Reports Q3 2026 Results with Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPY™

Published by Yahoo Finance · United States 8 h ago
Scienture Holdings, Inc.
Scienture Holdings, Inc. · Yahoo Finance

Detailed summary

First Nine Months of 2026 Revenue Increased Approximately 176% Year-Over-Year to $1.65 Million and Gross Profit Increased Approximately 145% to $1.41 Million COMMACK, NY, Nov. 16,…

Q3 2026 Revenue Increased Approximately 113% Year-Over-Year to $1.25 Million

Arbli™ generated approximately $330,000 and $730,000 of Net Product Revenue for Q3 2026 and the first nine months of 2026 respectively

Initial Wholesale Shipments of REZENOPY™ Generated Approximately $925,000 of Net Product Revenue Following Its August 2026 Launch

Q3 2026 Gross Profit Increased Approximately 77.5% Year-Over-Year to $1.02 Million

First Nine Months of 2026 Revenue Increased Approximately 176% Year-Over-Year to $1.65 Million and Gross Profit Increased Approximately 145% to $1.41 Million

COMMACK, NY, Nov. 16, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) ("Scienture" or the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the three and nine months ended September 30, 2026.

Third Quarter 2026 and Nine Months Ended September 30, 2026 Financial Highlights

Narasimhan Mani, President, Interim Chief Financial Officer and Co-Chief Executive Officer of Scienture, commented, "Our third-quarter results demonstrate the accelerating commercial momentum of Scienture as we begin generating meaningful revenue from two FDA-approved pharmaceutical products. Revenue increased approximately 265% sequentially to $1.25 million and more than doubled year-over-year. This growth reflects approximately $925,000 of net revenue from initial wholesale shipments of REZENOPY™ following its August launch, alongside continued progress with Arbli™.

Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture, stated, "Arbli™ continues to gain commercial traction, while the successful launch of REZENOPY™ has added a second revenue stream and established our presence in the…

Opening of the article, excerpted from Yahoo Finance. To read the rest, open the article on the publisher's site.

Read the full article on Yahoo Finance Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)

Also worth reading